ICR | 5 questions facing gene therapy in 2023

5 questions facing gene therapy in 2023

Sometime before the end of March, a person with the inherited blood disease beta thalassemia will receive an infusion containing hundreds of millions of their own stem cells. These cells will have just completed a round-trip journey to a drug manufacturing facility, where they’ll be equipped with a modified gene capable of fixing the patient’s condition.

The oldest independent membership-led professional body for clinical researchers across the globe.